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Mannheimia haemolytica serotype 1 (S1) is the most common bacterial isolate found in shipping fever
pneumonia in beef cattle. Currently used vaccines against M. haemolytica do not provide complete protection
against the disease. Research withM. haemolytica outer membrane proteins (OMPs) has shown that antibodies
to one particular OMP from S1, PlpE, may be important in immunity. In a recently published work, members
of our laboratory showed that recombinant PlpE (rPlpE) is highly immunogenic when injected subcutaneously
into cattle and that the acquired immunity markedly enhanced resistance to experimental challenge (A. W.
Confer, S. Ayalew, R. J. Panciera, M. Montelongo, L. C. Whitworth, and J. D. Hammer, Vaccine 21:2821-2829,
2003). The objective of this work was to identify epitopes of PlpE that are responsible for inducing the immune
response. Western blot analysis of a series of rPlpE with nested deletions on both termini with bovine anti-PlpE
hyperimmune sera showed that the immunodominant region is located close to the N terminus of PlpE. Fine
epitope mapping, in which an array of overlapping 13-mer synthetic peptides attached to a derivatized cellulose
membrane was probed with various affinity-purified anti-PlpE antibodies, identified eight highly reactive
regions, of which region 2 (R2) was identified as the specific epitope. The R2 region is comprised of eight
imperfect repeats of a hexapeptide (QAQNAP) and is located between residues 26 and 76. Complement-
mediated bactericidal activity of affinity-purified anti-PlpE bovine antibodies confirmed that antibodies di-
rected against the R2 region are effective in killing M. haemolytica.
Bovine respiratory disease arises from the interaction of
numerous contributing factors, including physical stresses as-
sociated with weaning, shipment, inclement weather, and over-
crowding coupled with viral and bacterial infections (8, 31, 32,
59, 63). The result in severe cases is colonization of the lungs
with pathogenic bacteria resulting in severe pneumonia. Pas-
teurella multocida, Haemophilus somnus, and Mannheimia (for-
merly Pasteurella) haemolytica are associated with bovine
pneumonia. However, M. haemolytica serotype 1 (S1) is by far
the most important bacterial pathogen in the development of
the often-fatal fibrinous pleuropneumonia in beef cattle known
as pneumonic pasteurellosis or shipping fever (31, 32).
Immunity against M. haemolytica is thought to be primarily
through production of serum antibodies that neutralize the
secreted leukotoxin (LKT) and antibodies against surface an-
tigens (45). The mechanism of activity of antisurface antibod-
ies and the specific surface antigens involved in anti-M. hae-
molytica immunity are not known; however, complement-
mediated bacterial lysis and bacterial phagocytosis and killing
are thought to be important in defense against M. haemolytica
infection (45). Complement-mediated bactericidal activity
against M. haemolytica and phagocytosis of M. haemolytica by
bovine neutrophils has been demonstrated with bovine im-
mune serum (12, 17, 40, 46).
Little is known about the specific surface antigens that are
important in stimulating host immunity to M. haemolytica.
However, several studies point toward the importance of outer
membrane proteins (OMPs). Pandher et al. (45) identified 21
surface-exposed immunogenic OMPs in M. haemolytica S1 by
protease treatment and Western blotting. High antibody re-
sponses to several specific OMPs correlated with resistance to
challenge with virulent M. haemolytica S1 (18, 43). Vaccination
of cattle with OMP-enriched cellular fractions from M. hae-
molytica S1 also significantly enhanced the resistance of cattle
to experimental challenge (42) even in the absence of antibod-
ies to LKT.
A major 45-kDa OMP was one of the M. haemolytica OMPs
to which high antibody responses correlated with resistance to
experimental challenge (43). In 1999, Pandher et al. (46) re-
ported the cloning, sequencing, and characterization of the
gene encoding the 45-kDa M. haemolytica S1 OMP (designated
PlpE), which was found to be genetically similar to an immu-
nogenic lipoprotein (OmlA) of Actinobacillus pleuropneumo-
niae serotypes 1 and 5 (34). Affinity-purified anti-PlpE anti-
bodies recognized an OMP of similar size in all serotypes of M.
haemolytica except serotype 11 (46), which was later classified
as Mannheimia glucosida. In addition, PlpE is surface exposed
and immunogenic in cattle, and in complement-mediated kill-
ing assays, a significant reduction in killing of M. haemolytica
occurred when bovine immune serum was depleted of anti-
PlpE antibodies (43). Our laboratory recently cloned and ex-
pressed the gene for M. haemolytica OMP PlpE, and the
recombinant PlpE (rPlpE) was purified and used in immuno-
logical and vaccination studies (15). In that study, rPlpE with
an adjuvant was shown to be highly immunogenic in cattle and
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vaccination of cattle with 100 g of rPlpE markedly enhanced
resistance to experimental challenge with virulent M. haemo-
lytica (15). Finally, the addition of rPlpE to a commercial M.
haemolytica vaccine significantly enhanced (P  0.05) the pro-
tection afforded by the vaccine against experimental challenge
(15). All of these results indicate that antibodies against PlpE
may significantly contribute to host defense against the bacte-
rium.
Since extended portions of the molecule are predicted to be
buried in the outer membrane, most of the OMP molecule
would play no significant role in inducing protective immune
responses. Only short, surface-exposed epitopes of these pro-
teins represent the major immunogenic regions of the protein.
Identification of such surface-exposed epitopes as protective
antigens in animal models has been the goal of peptide vaccine
design strategies for various pathogenic bacteria including
nontypeable Haemophilus influenzae (3, 4, 44), Pseudomonas
aeruginosa (62), Neisseria meningitidis (61), and Streptococcus
mutans (48). Since the M. haemolytica PlpE is an important
immunogen, this study was undertaken to characterize surface-
exposed and immunologically important epitopes of this OMP.
MATERIALS AND METHODS
Bacterial strains and growth conditions. M. haemolytica 89010807N (45),
which is S1, was used as a source of the plpE gene (43) and in complement-
mediated bactericidal assays. The organism was routinely cultured in brain heart
infusion (BHI) broth or on BHI blood agar plates (Hardy Diagnostics, Mesa,
Ariz.) supplemented with 5% sheep blood. Escherichia coli DH5 (Invitrogen,
Carlsbad, Calif.) was used for subcloning and propagation of recombinant plas-
mids. Recombinant proteins were overexpressed in and purified from E. coli
BL21(DE3) or BL21(DE3)(pLysS) (Novagen, Madison, Wis.). E. coli strains
were grown on Luria-Bertani (LB) medium supplemented with the appropriate
antibiotic when needed. All plates were incubated at 37°C with 5% CO2.
Construction of recombinant plasmids containing deletions in plpE. Trun-
cated forms of the plpE gene carrying various deletions were generated from M.
haemolytica 89010807N genomic DNA by PCR with the primers listed in Table
1. PCR products were cut with BamHI plus EcoRI or BamHI plus HindIII and
ligated to pRSETA (Invitrogen) and/or pET28 (Novagen) that were cut with the
same pair of enzymes. Chemically competent E. coli DH5 (Invitrogen) cells
were transformed with 1 to 5 l of the ligation mixture and plated on LB agar
plates supplemented with either 50 g of carbenicillin/ml or 30 g of kanamycin/
ml. Transformants were screened by restriction enzyme analysis, and appropriate
subclones were identified. Plasmid DNA isolated from such subclone was sub-
mitted to the Oklahoma State University Core Facility where the nucleotide
sequence was determined with the ABI model 3700 (Applied Biosystems, Foster
City, Calif.) automated DNA sequencing system. Nucleotide sequences of rep-
resentative subclones were compared to that deposited in GenBank (accession
no. AF059036). The final eight recombinant plasmids constructed in this study
and the truncated recombinant proteins they encode are listed in Table 2.
Expression and purification of truncated forms of rPlpE. Each recombinant
plasmid listed in Table 2 was introduced into BL21(DE3)(pLysS) cells (Novagen)
to express and purify recombinant forms of PlpE with His tags on their N termini
according to the manufacturer’s protocols. Briefly, single colonies of
BL21(DE3)(pLysS) harboring the truncated plpE in pRSETA or pET28 were
inoculated into 250 to 500 ml of LB broth supplemented with 50 g of carben-
icillin/ml and 34 g of chloramphenicol/ml (pRSETA-based constructs) or 30 g
of kanamycin/ml and 34 g of chloramphenicol/ml (pET28-based constructs).
The cultures were incubated at 37°C until reaching an absorbance (A600) of 0.5,
at which time expression was induced by adding isopropyl--D-galactopyranoside
(IPTG) to a final concentration of 1 mM. Induction was continued for at least
3 h. Cells were then harvested by centrifugation at 10,000  g at 4°C, resus-
pended in binding buffer (6 M urea, 500 mM NaCl, 20 mM Tris-HCl, 5 mM
imidazole [pH 7.9]), and lysed by applying 20,000 lb/in2 in an Aminco French
pressure cell (SLM Instruments, Inc., Rochester, N.Y.). Cellular debris was
removed by centrifugation at 14,000  g for 30 min at 4°C, and the supernatant
containing the recombinant protein was passed through a 0.45-m-pore-size
filter (Nalge Nunc, Rochester, N.Y.). The clarified supernatant was loaded onto
a 10-mg-binding-capacity His•Bind column (Novagen) prepacked with Ni2-
charged His•Bind resin that was preequilibrated with 10 ml of binding buffer.
Unbound proteins were removed by applying 10 ml of binding buffer followed by
10 ml of wash buffer (6 M urea, 500 mM NaCl, 20 mM imidazole, and 20 mM
Tris-HCl [pH 7.9]). The recombinant protein was then eluted in small fractions
with an elution buffer (6 M urea, 1 M imidazole, 250 mM NaCl, 10 mM Tris-HCl
[pH 7.9]). Fractions containing the recombinant protein were pooled and dia-
lyzed against phosphate-buffered saline (PBS) containing decreasing concentra-
tions of urea to remove the denaturant and, at the same time, aid in the refolding
of the recombinant protein. The identity, purity, and integrity of purified proteins
were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) followed by Coomassie staining and Western blotting with murine
anti-PlpE polyclonal ascites.
Production of polyclonal mouse ascites. Anti-PlpE polyclonal mouse ascites
was produced by the Hybridoma Center of Oklahoma State University. Briefly,
TABLE 1. PCR primers used in this study
Name Sequence (5–3)a Orientationb Targetnucleotidesc
plpEBH GTCAggatccTGCGGAGGAAGCGGTAGC F 198–215
plpEER GACTgaattcTTATTTTTTCTCGCTAACCATTA R 1208–189
plpBM-1 CTTggatccCAAGCACAAAATGTT F 282–296
plpBM-2 CCTggatccCAAGCAGAGGTTACT F 426–440
plpBM-3 ATTggatccAATGCTGAACAACTC F 648–662
HNplp-1 GATaagcttTTACCGTGCGGCAAATTC R 890–876
HNplp-2 AAAaagcttTTATTTAATTTCTACATC R 920–906
HNplp-3 TTTaagcttTTATATACTTCCTTGAGC R 950–936
a Lowercase portions of sequences are restriction sites.
b F, forward; R, reverse.
c Numbering is according to GenBank accession no. AF059036.
TABLE 2. Plasmid constructs used in this study, characteristics of
recombinant proteins, and binding properties of anti-PlpE
antibodies, determined densitometrically
Plasmid Recombinantprotein
Deleted
region
(amino
acids)
Binding capacity of anti-
PlpE antibodies
Vola (INT/
mm2) % Binding
pSAC3 rPlpE (pRSETA) 0b 2,472 100
pSAC30 rPlpEC106 232–337 2,333 94.3
pSAC31 rPlpEC96 242–337 2,450 99.1
pSAC32 rPlpEC86 252–337 2,635 106
pSAC63 rPlpEN28 1–28 2,528 102
pSAC64 rPlpEN76 1–76 699 28.0
pSAC65 rPlpEN150 1–150 310 12.5
pSAC67 rPlpE (pET28) 0b 2,472 100
a Sum of the intensities of the pixels inside the volume boundary  area of a
single pixel (in millimeters squared).
b Mature rPlpe with 337 amino acids.
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three female Swiss Webster (CFW) mice (Charles River Laboratories, Wilming-
ton, Mass.) were immunized three times with 50 g of truncated rPlpE diluted
in RIBI (Corixa Corp., Seattle, Wash.) adjuvant. The first immunization was
given subcutaneously. The second immunization was given intraperitoneally after
14 days and repeated 10 days later. A test bleed was performed, and the sera
were screened for antibodies to rPlpE by enzyme-linked immunosorbent assay
(ELISA). Because the antibody titer was less than 1:3,200, two additional intra-
peritoneal immunizations were given at 10-day intervals. The mice were then
injected with approximately 2 106 sarcoma cells (catalog no. TIB-66; American
Type Culture Collection, Manassas, Va.). Between 7 and 10 days after sarcoma
injection, ascites was removed from each mouse three times. A total of 4 to 18
ml of ascitic fluid was removed from each mouse before euthanization.
Bovine antisera. PlpE-specific sera were obtained from 6- to 8-month-old
calves that were used for immunogenicity studies of rPlpE (15). Sera from these
calves were screened for anti-M. haemolytica antibodies, as measured by ELISA,
to formalin-killed M. haemolytica whole cells (16, 18). Calves that had anti-M.
haemolytica antibody concentrations of less than 0.50 ng of immunoglobulin G
binding to the antigen at a 1:400 serum dilution (normal background) were used
in this study. Each of three calves was vaccinated once with 10, 50, or 100 g of
rPlpE in a commercial proprietary adjuvant (Pfizer, Inc., Lincoln, Neb.) and, on
TABLE 3. Overlapping peptides spanning PlpEa
No. Mol wt Peptide sequence No. Mol wt Peptide sequence
1 1,022.4 CGGSGSGGSSSTP
2 1,153.4 SGSGGSSSTPNHP
3 1,246.5 GGSSSTPNHPKPV
4 1,354.6 SSTPNHPKPVLVP
5 1,436.6 PNHPKPVLVPKTQ
6 1,429.6 PKPVLVPKTQNNL
7 1,434.3 VLVPKTQNNLQAQ
8 1,433.2 PKTQNNLQAQNVP
9 1,433.9 QNNLQAQNVPQAQ
10 1,350.0 LQAQNVPQAQNAS
11 1,364.8 QNVPQAQNASQAQ
12 1,305.9 PQAQNASQAQNAP
13 1,336.8 QNASQAQNAPQAQ
14 1,305.9 SQAQNAPQAQNAP
15 1,346.8 QNAPQAQNAPQAQ
16 1,315.9 PQAQNAPQAQNAP
17 1,375.9 QNAPQAQNAPQVE
18 1,345.0 PQAQNAPQVENAP
19 1,375.9 QNAPQVENAPQAQ
20 1,345.0 PQVENAPQAQNAP
21 1,377.0 ENAPQAQNAPQVE
22 1,345.0 PQAQNAPQVENAP
23 1,377.0 QNAPQVENAPQAE
24 1,361.1 PQVENAPQAEVTP
25 1,330.2 ENAPQAEVTPPVP
26 1,369.0 PQAEVTPPVPQPQ
27 1,416.1 EVTPPVPQPQSQK
28 1,372.2 PPVPQPQSQKIDG
29 1,428.3 PQPQSQKIDGSFD
30 1,404.6 QSQKIDGSFDKIG
31 1,375.9 KIDGSFDKIGSVK
32 1,374.9 GSFDKIGSVKLNK
33 1,411.7 DKIGSVKLNKEAQ
34 1,398.6 GSVKLNKEAQTLE
35 1,511.8 KLNKEAQTLELSR
36 1,517.8 KEAQTLELSRFTL
37 1,531.8 QTLELSRFTLVDK
38 1,460.9 ELSRFTLVDKLGT
39 1,453.9 RFTLVDKLGTPPK
40 1,439.9 LVDKLGTPPKFDK
41 1,355.8 KLGTPPKFDKVSG
42 1,426.9 TPPKFDKVSGKKI
43 1,503.0 KFDKVSGKKIIEE
44 1503.0 KVSGKKIIEEKDF
45 1,514.1 GKKIIEEKDFLVL
46 1,515.0 IIEEKDFLVLNLS
47 1,501.9 EKDFLVLNLSDIN
48 1,457.7 FLVLNLSDINAEQ
49 1,355.6 LNLSDINAEQLSG
50 1,390.6 SDINAEQLSGDFL
51 1,500.8 NAEQLSGDFLIRR
52 1,503.8 QLSGDFLIRRSDD
53 1,599.1 GDFLIRRSDDLFY
54 1,663.2 LIRRSDDLFYGYY
55 1,634.0 RSDDLFYGYYHDT
a Peptides comprising R2 are shown in boldface type.
56 1,575.0 DLFYGYYHDTNGK
57 1,525.9 YGYYHDTNGKNLV
58 1,399.7 YHDTNGKNLVDAA
59 1,374.7 TNGKNLVDAADKF
60 1,480.7 KNLVDAADKFSQY
61 1,470.6 VDAADKFSQYFVV
62 1,592.7 ADKFSQYFVVYDE
63 1,661.8 FSQYFVVYDEKRV
64 1,642.8 YFVVYDEKRVNDN
65 1,548.7 VYDEKRVNDNISD
66 1,513.8 EKRVNDNISDKLT
67 1,435.7 VNDNISDKLTATY
68 1,520.0 NISDKLTATYRKK
69 1,539.0 DKLTATYRKKEGF
70 1,501.9 TATYRKKEGFVYG
71 1,526.9 YRKKEGFVYGSNP
72 1,445.8 KEGFVYGSNPHTK
73 1,478.8 FVYGSNPHTKEFA
74 1,409.8 GSNPHTKEFAARI
75 1,480.0 PHTKEFAARISKL
76 1,415.9 KEFAARISKLGDV
77 1,381.9 AARISKLGDVEIK
78 1,473.9 ISKLGDVEIKFEN
79 1,401.6 LGDVEIKFENGQA
80 1,388.4 VEIKFENGQAQGS
81 1,403.5 KFENGQAQGSIKD
82 1,371.4 NGQAQGSIKDEKD
83 1,314.5 AQGSIKDEKDGNA
84 1,447.8 SIKDEKDGNAEIF
85 1,461.8 DEKDGNAEIFTIK
86 1,362.7 DGNAEIFTIKGDT
87 1,445.8 AEIFTIKGDTKQL
88 1,475.8 FTIKGDTKQLETT
89 1,441.6 KGDTKQLETTPTE
90 1,498.6 TKQLEITPTESNR
91 1,480.9 LEITPTESNRIII
92 1,422.9 TPTESNRIIIAIL
93 1,480.8 ESNRIIIAILDQN
94 1,493.8 RIIIAILDQNQKS
95 1,472.6 IAILDQNQKSYTP
96 1,492.5 LDQNQKSYTPGME
97 1,448.7 NQKSYTPGMEKAI
98 1,439.8 SYTPGMEKAIMET
99 1,477.0 PGMEKAIMETKFI
100 1,522.0 EKAIMETKFIDSK
101 1,435.9 IMETKFIDSKAGN
102 1,392.6 TKFIDSKAGNSDQ
103 1,420.7 IDSKAGNSDQKYL
104 1,404.7 KAGNSDQKYLIGE
105 1,434.7 NSDQKYLIGEAKS
106 1,533.8 QKYLIGEAKSDNW
107 1,426.7 LIGEAKSDNWQAI
108 1,460.6 EAKSDNWQAIMVS
109 1,517.7 SDNWQAIMVSEKK
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day 23, had endpoint antibody titers of 1:12,800, 1:25,600, and 1:25,600, respec-
tively, as measured by an ELISA for rPlpE (15). A nonvaccinated calf had an
endpoint titer of only 1:400. In that study, rPlpE-vaccinated calves were subse-
quently challenged with 5.0  109 CFU of virulent M. haemolytica and had
between 71 and 81% smaller lung lesions than did the M. haemolytica-challenged
nonvaccinated calf (15).
Anti-M. haemolytica serum was obtained from a weanling beef calf that spon-
taneously developed high anti-M. haemolytica antibodies with an endpoint titer
of 1:25,600 after natural exposure. Serum was also available from a calf that had
been subcutaneously vaccinated twice, 14 days apart, with 2 ml of 109 CFU of live
M. haemolytica each time. The serum was obtained 14 days after the last vacci-
nation and had an endpoint titer to PlpE of 1:25,600.
Preparation of affinity columns and purification of anti-PlpE antibodies.
Purified rPlpE was coupled to N-hydroxylsuccinimide (NHS)-activated Sepha-
rose 4 Fast Flow (Amersham Biosciences, Uppsala, Sweden) according to the
manufacturer’s recommendations. Briefly, defined bed volumes of NHS-acti-
vated Sepharose 4 Fast Flow in an Econo column (Bio-Rad, Hercules, Calif.) was
washed with 10 to 15 volumes of cold 1 mM HCl and equilibrated with PBS.
Purified rPlpE (3 to 7 mg) in PBS was mixed with a 2-ml bed volume in a ratio
of 0.5:1 (coupling solution and medium), and the column was incubated at 4°C
on a rocking platform overnight. The nonreacted groups were blocked by 0.1 M
Tris (pH 8.0) and washed with alternating high- and low-pH buffers (Tris-HCl
[pH 8.0] and acetate buffer [pH 4.0], respectively). An affinity column was
prepared for each truncated rPlpE as well as for whole rPlpE.
Anti-rPlpE antibodies against specific regions of PlpE were purified by using
the affinity columns described above. A column with NHS-activated Sepharose
coupled to an rPlpE of interest was fitted with a flow adaptor according to the
recommendation of the manufacturer (Bio-Rad) and equilibrated with Dulbec-
co’s PBS (DPBS) at a flow rate of 1 ml/min. Hyperimmune serum produced by
immunizing calves with full-length rPlpE was diluted 1:10 with DPBS and passed
through Nalgene 0.45-m-pore-size PES filters (Nalge). The filtered serum was
then applied to the equilibrated column via a peristaltic pump (pump P-1;
Pharmacia LKB) at a flow rate of 1 ml/min. The flowthrough was reapplied to the
column several times to reextract the serum by connecting the flowthrough to the
reservoir of the initial serum. The column was then washed with DPBS until
complete removal of nonspecific proteins was achieved, as determined by a UV
monitor (optical unit UV-1; Pharmacia LKB) attached to a chart recorder. The
specifically bound antibody was eluted with glycine buffer (100 mM glycine, 140
mM NaCl [pH 3.0]) by collecting fractions into microcentrifuge tubes containing
a 1/10 volume of 1 M Tris-HCl (pH 8.0). The absorbance of fractions was
determined at 280 nm, and those having a reading of at least two to three times
that of the background were pooled and dialyzed overnight against DPBS at 4°C
in a Slide-A-Lyzer dialysis cassette (Pierce, Rockford, Ill.). The concentration of
affinity-purified antibodies was determined with a BCA protein assay kit (Pierce).
Specific antibodies against rPlpE with 28-, 76-, and 150-amino-acid deletions on
their N termini, rPlpEN28 (pSAC63), rPlpEN76 (pSAC64), and rPlpEN150
(pSAC65), respectively, were purified as described previously.
Antibodies against regions of PlpE that are exposed on the surfaces of M.
haemolytica cells were purified as previously described (45, 60). Briefly, intact M.
haemolytica cells from 500 ml in late log phase were harvested by centrifugation
and washed with PBS. The washed cells were resuspended in 10 ml of a 1:10
dilution of hyperimmune bovine anti-rPlpE serum or anti-PlpE mouse ascites
diluted in PBS on ice for 2 to 4 h with gentle agitation. The cells were pelleted
and washed several times with PBS. The antibodies bound to the surface were
eluted by resuspending and agitating the cells in 2 ml of 0.1 M glycine and 140
mM NaCl (pH 3.0) for at least 30 min. The cells were centrifuged at 14,000  g,
and the eluted antibodies were collected in the supernatant, which was neutral-
ized immediately by adding a 1/10 volume of 1 M Tris (pH 8.0).
Epitope mapping of PlpE by peptide array. A peptide array comprising a total
of 109 overlapping 13-mer peptides with a 3-amino-acid offset (Table 3) was
custom made by Sigma-Genosys LP (The Woodlands, Tex.). Briefly, the synthe-
sis of peptides was performed on cellulose membranes in which hydroxyl func-
tions of a commercially available filter paper were derivatized with 9-fluorenyl-
methoxy carbonyl-B-alanine (Fmoc-B-Ala) with subsequent removal of the
Fmoc group. The synthesis areas were defined by spotting an Fmoc-B-alanine-
pentafluorophenyl ester solution to distinct areas on the membrane. Blocking the
remaining amino functions between spots provided discrete reaction sites on the
membrane for further standard solid-phase peptide synthesis with amino acid
pentafluorophenyl esters. Peptides remained covalently attached to the cellulose
membrane by the C terminus and had a free N terminus.
Typically, prior to blotting, the membrane was blocked with SuperBlock dry
blend (Pierce) blocking buffer in Tris-buffered saline (TBS) (pH 7.4). All incu-
bations were done at room temperature. The membrane was then incubated in
blocking buffer containing primary antibody at a dilution of 1:1,000 to 1:5,000 for
an hour. Following several washes with TBS (pH 7.4) supplemented with 0.05%
Tween 20 and 0.2% Triton X-100 (TBSTT), the membrane was incubated in
SuperBlock containing a goat anti-bovine or anti-mouse secondary antibody
conjugated to horseradish peroxidase (HRP) (Kirkegaard & Perry Laboratories,
Inc., Gaithersburg, Md.) at dilutions of 1:100,000 to 1:200,000 for 1 h. The
membrane was washed several times with TBSTT, incubated with SuperSignal
West Pico chemiluminescent substrate (Pierce) working solution (0.125 ml/cm2)
for 5 min, placed in a plastic membrane protector, and exposed to a CL-X Posure
X-ray film (Pierce) for various durations of time. The X-ray film was then
developed in a Konica (Wayne, N.J.) SRX-101A medical film processor. The
developed X-ray film was scanned on an Arcus 1200 Agfa scanner (Taipei,
Taiwan), and scanned images were analyzed with the Gene Pix Pro, version 4.0
(Axon Instruments, Union City, Calif.). Signal intensities were defined as the
median pixel intensity following the subtraction of the local median background
signal. The peptide array was stripped with Restore Western blot stripping buffer
(Pierce) according to the procedure recommended by the manufacturer. Com-
plete stripping was confirmed by autoradiography. The blot procedure was re-
peated several times with anti-PlpE antibodies obtained from different sources or
purified in a variety of ways.
The peptide array was sequentially probed according to the manufacturer’s
recommendations. Nonspecifically binding spots were initially identified by prob-
ing the peptide array with HRP-conjugated goat anti-bovine and rabbit anti-
bovine secondary antibodies. The membrane was then probed with a naive serum
obtained from a colostrum-deprived newborn calf to further identify spots that
nonspecifically bound bovine antibodies. Finally, the peptide array was probed
with antibodies produced against PlpE by either vaccination with rPlpE or live M.
haemolytica or by natural exposure.
Complement-mediated bactericidal assay. Serum from a newborn colostrum-
deprived Holstein calf was used as a source of complement. Sources of antibod-
ies used in the complement-mediated bactericidal assay were hyperimmune sera
from calves vaccinated with the full-length rPlpE and affinity-purified antibodies
with the affinity columns described above. Each of these antibodies, with the
FIG. 1. Twenty and 40 l of whole-cell lysate (lanes 1 and 2), the
same volumes of outer membrane proteins (lanes 3 and 4), and 0.5 and
1.0 g of rPlpE (lanes 5 and 6) were separated by SDS–12.5% PAGE.
M, molecular mass markers. One gel was stained with Coomassie
brilliant blue (A), and the second was transferred onto nitrocellulose
for a Western blot with hyperimmune calf serum immunized with
rPlpE (B).
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FIG. 2. Predicted features of the deduced amino acid sequence of PlpE showing regions that are potentially antigenic, hydrophilic, and surface
exposed and secondary structures.
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exception of the complement source, was incubated at 56°C for 30 min to
inactivate resident complement prior to use.
The complement-mediated killing assay was performed as previously de-
scribed (45), except that a decapsulation procedure (12) was added. Decapsula-
tion was done to maximize the exposure of surface protein epitopes to anti-PlpE
antibodies (12). Briefly, well-isolated colonies of M. haemolytica 89010807N from
overnight growth on BHI blood agar plates were transferred into tubes with BHI
broth and grown in a shaker-incubator (200 rpm) at 37°C overnight. The over-
night starter culture was transferred into a 125-ml conical flask containing 50 ml
of BHI and incubated at 37°C in a shaker-incubator for 2 to 3 h. The cells were
pelleted, washed once with PBS, resuspended in 40 ml of PBS, and decapsulated
by incubation at 41°C with 100-rpm shaking for 1 h to remove the polysaccharide
capsule (12). The decapsulated cells were resuspended in PBS to an A600 of 0.50.
A 1:1,000 dilution of the latter was used in a killing assay. The assay, plating, and
incubation were done as previously described (45). In each assay, heat-inacti-
vated antibodies without any complement source and complement source with-
out antibodies were used as negative controls. The percent killing was calculated
with the following formula: % killing 	 [(CFUt0 
 CFUt30)/CFUt0](100%).
Western blotting. Whole-cell lysates, outer membrane preparations of M.
haemolytica or rPlpE, were resolved on SDS–12.5% PAGE gels by electrophore-
sis and transferred onto 0.2-m nitrocellulose membranes in a Mini Trans-Blot
cell (Bio-Rad). Membranes were blocked with TBS containing 1% casein for 1 h
at room temperature. Each membrane was transferred into blocking buffer
containing an appropriately diluted anti-PlpE antibody, where it was incubated
for 1 h at room temperature. Following extensive washing with TBSTT, bound
antibodies were detected by either alkaline phosphatase-conjugated goat anti-
bovine or anti-mouse antibodies with 5-bromo-4-chloro-3-indolyl-phosphate
(BCIP)–nitroblue tetrazolium as the substrate (Kirkegaard & Perry Laborato-
ries).
ELISA. ELISA was performed as described previously (14). Briefly, high-
binding, 96-well, flat-bottom polystyrene Costar 9018 (Corning Inc., Corning,
N.Y.) plates were coated with 0.5 g of recombinant protein/ml in coating
solution (12.8 mM Na2CO3, 34.8 mM NaHCO3 [pH 9.6]) at 4°C overnight or at
37°C for 2 h on a rocking platform. The plates were washed four times with 1
PBS supplemented with 0.05% Tween (PBST) (Sigma, St. Louis, Mo.) and
blocked with PBST–1% bovine serum albumin for 1 h at room temperature.
Primary bovine or murine antibody diluted in PBS–1% bovine serum albumin
was added to the wells and incubated at 37°C for 1.5 h. In most instances, an
initial 1:400 dilution followed by twofold serial dilutions of the primary antibody
were used. After washing with PBST, a 1:400 dilution of goat anti-mouse or goat
anti-bovine HRP conjugate (Kirkegaard & Perry Laboratories) was added and
the plates were incubated at 37°C for 1 h and 30 min. Following washing with
PBST, o-phenylenediamine tablets (Amresco, Solon, Ohio) were reconstituted
and used as the substrate according to the manufacturer’s recommendations.
The absorbance at 490 nm was determined for each well by using a Vmax kinetic
microplate reader (Molecular Devices, Sunnyvale, Calif.).
RESULTS
Immunogenicity of rPlpE. The purity of the rPlpE prepara-
tion (Fig. 1A) and the specificity of the immune response of an
rPlpE-vaccinated calf were evident (Fig. 1B), in that PlpE in
the OMP and whole-cell lysate was demonstrated. Evidence of
mild proteolysis in the Western blots and several trace con-
taminants were seen on the stained gel.
Epitope mapping with truncated rPlpE. Computer analysis
of the deduced amino acid sequence of PlpE with MacVector,
version 7.2.2 (Accelrys, Inc., San Diego, Calif.), which employed
algorithms such as antigenic index (47), hydrophilicity (38), and
surface probability (36), revealed the presence of putative anti-
genic regions randomly distributed throughout the protein (Fig.
2). To determine whether this was true, we constructed a series of
truncated proteins. A total of six plasmid constructs (pSAC30,
pSAC31, pSAC32, pSAC63, pSAC64, and pSAC65) carrying the
plpE gene with various deletions were made (Table 2). Western
blot analysis clearly demonstrated that all of the six truncated
forms of rPlpE and the full-length protein reacted with hyperim-
mune serum from calves immunized with full-length rPlpE.
Quantitation of the respective bands on a Western blot (Fig. 3) in
which equal amounts of each recombinant protein were resolved
on SDS–12.5% PAGE gels demonstrated substantial differences
in the intensities of the reactions of hyperimmune serum with the
truncated recombinant proteins (Table 2). There was no appre-
ciable difference in the intensity of the reaction between rPlpE
(lane 1) and pSAC63 (rPlpEN28) (lane 2), lacking the N-termi-
nal 28 amino acids. There were also no differences in the intensity
of binding between rPlpE and mutants carrying 86 (rPlpEC86),
96 (rPlpEC96), and 106 (rPlpEC106) amino acid deletions on
the C terminus of PlpE (lanes 3, 4, and 5, respectively). In con-
trast, the binding capacity of antibodies to mutants carrying de-
letions on their N termini decreased with increasing deletions.
The reactivity to pSAC64 (rPlpEN76) (lane 6), which carries a
deletion of 76 amino acids on the N terminus, decreased to 28%,
a reduction of 72% compared to rPlpE. Further deletion of the N
terminus, as seen with pSAC65 (rPlpEN150) (lane 7), reduced
the binding capacity of immunoglobulins to the truncated protein
to 12.5%. These findings clearly indicate that the region between
residues 28 and 76 from the N terminus of PlpE carries a stretch
of amino acids with possible epitope(s) that may be responsible
for inducing the immune response elicited when rPlpE is used as
a vaccine.
Fine mapping of epitopes on PlpE. To further localize
epitopes on PlpE, an array of overlapping peptides was probed
with immune sera. A total of eight discrete highly reactive
regions were identified when the peptide array was sequen-
tially probed as described (Fig. 4). HRP-conjugated goat and
rabbit anti-bovine secondary antibodies were reactive to re-
gions 1, 3, 4, 7, and 8 (Fig. 4A and B, respectively). When naive
serum from a colostrum-deprived newborn calf was used to
test the peptide array, regions 5 and 6 were identified in addi-
tion to those already mentioned (Fig. 4C). When antibodies
obtained from calves that were immunized with rPlpE, live M.
haemolytica, or natural exposure to M. haemolytica were used
to probe the peptide array, all eight of the regions were found
to be highly reactive (Fig. 4D). When the nonspecific regions,
i.e., 1, 3, 4, 5, 6, 7, and 8 were subtracted from those that
reacted with hyperimmune sera produced against PlpE, region
FIG. 3. Nested deletion mutants were tested for binding capacity of
anti-rPlpE antibodies from bovine and murine sources. 1, rPlpE; 2,
rPlpEN28; 3, rPlpEC86; 4, rPlpEC96; 5, rPlpEC106; 6, rPlpE
N76; 7, rPlpEN150. (A) Anti-PlpE bovine hyperimmune serum;
(B) anti-His-tagged mouse monoclonal antibody; (C) Coomassie stain.
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FIG. 4. Overlapping 13-mer peptides spanning PlpE were sequentially probed with a variety of antibodies. (A) Goat anti-bovine-HRP;
(B) rabbit anti-bovine-HRP; (C) colostrum-deprived calf serum (naive); (D) bovine anti-PlpE hyperimmune serum; (E) immunodominant epitope
(R2) identified by subtracting the background, i.e., panels A, B, and C from panel D. The clusters of peaks also known as regions (R) are numbered
from left to right as they appear in panel D (R1, peptides 5 to 7; R2, peptides 13 to 26; R3, peptides 31 to 34; R4, peptides 39 to 44; R5, peptides
53 to 55; R6, peptides 62 to 64; R7, peptides 68 to 71; R8, peptides 75 to 77). The arrow shows the immunodominant epitope region (R2) of the
PlpE protein.
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2 (R2), corresponding to amino acids 37 to 79 of the PlpE
sequence, remained (Fig. 4E) the immunodominant region of
PlpE.
Bactericidal activities of anti-PlpE antibodies. To determine
whether immune sera produced against the purified rPlpE
would have complement-mediated cell killing activity, hyper-
immune sera from calves immunized with rPlpE were tested
for their ability to promote complement-mediated killing of
the homologous strain M. haemolytica 89010807N. Sera from
calves vaccinated with rPlpE exhibited bactericidal activity of
98 to 100% in the presence of a complement source (Fig. 5).
Complement-mediated cell killing activities of anti-rPlpE
antibodies that were purified on rPlpEN28, rPlpEN76,
rPlpEN150, or rPlpE affinity columns confirmed the results
of the binding studies described above (Fig. 5 and Table 2).
There was no difference in the complement-mediated cell kill-
ing activity of anti-rPlpE antibodies purified on rPlpEN28
and rPlpE affinity columns and that exhibited by the whole
anti-rPlpE antiserum, in that all showed almost 100% killing
activity (Fig. 5). The flowthrough from each of the above pu-
rifications had a bactericidal activity that was significantly re-
duced to 17 to 21% (P  0.00002). On the other hand, the
complement-mediated bactericidal activity of anti-rPlpE anti-
bodies purified on rPlpEN76 and rPlpEN150 affinity col-
umns were only 25 and 40%, respectively, which is significantly
lower (P  0.0001) than those exhibited by anti-rPlpE anti-
bodies purified by rPlpEN28 and rPlpE affinity columns. The
flowthrough sera depleted by rPlpEN76 and rPlpEN150
affinity columns showed a killing activity of65%, demonstrat-
ing that the absorption did not significantly reduce (P  0.05)
the bactericidal activity of anti-PlpE sera. These results indi-
cate that complement-mediated bactericidal activity is associ-
ated with anti-rPlpE antibodies that are directed against
epitope located in R2.
DISCUSSION
Numerous attempts have been made previously to de-
velop efficacious vaccines against M. haemolytica. These in-
clude live M. haemolytica (2, 6, 7, 9, 11, 19, 21, 33, 50), killed
M. haemolytica cells (10, 20, 22, 23, 52), components or
fractions of M. haemolytica cells (17, 24, 27, 28, 35, 49,
53–55), and commercial vaccines (57, 58). While immunity
to M. haemolytica appears to require anti-LKT and anti-
surface antigen antibodies (55), partial protection could be
afforded to cattle experimentally vaccinated with M. haemo-
lytica preparations that did not contain LKT (21, 40). The
partial protection against challenge was not attributed to
any specific protein until Pandher et al. (45) cloned the plpE
gene and showed that absorption of anti-PlpE sera with E.
coli expressing the PlpE protein could substantially reduce
complement-mediated bactericidal activity.
It was previously shown that vaccination with rPlpE en-
hances resistance to M. haemolytica challenge and augments
commercial vaccine-induced immunity, suggesting that this is
an important surface antigen (15). Epitope mapping of the
PlpE protein by measuring the binding of anti-PlpE antibodies
to truncated rPlpE molecules demonstrated that the major
FIG. 5. Complement-mediated bacterial killing activity of anti-PlpE antibodies purified by affinity columns with intact rPlpE, deletion deriv-
atives of rPlpE as ligands, and whole serum from a calf that was immunized with rPlpE and from a colostrum-deprived newborn calf.
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epitopes of this protein lie within the N terminus between
amino acids 28 and 76. This region of the polypeptide con-
tains eight imperfect tandem repeats of the hexapeptide
QAQNAP (45). Further evaluation by peptide array analysis
demonstrated that R2, between residues 36 and 76, is the
major epitopic region. The use of deletion mutants to ad-
sorb anti-rPlpE antibodies further demonstrated that anti-
bodies to R2 are involved in complement-mediated killing
of M. haemolytica. Taken together, these results provide
solid evidence that R2 of PlpE is surface exposed, immuno-
dominant, and important in stimulating antibodies capable
of killing M. haemolytica.
In silico analysis of the deduced amino acid sequence of R2
with algorithms such as Parker’s antigenicity (47), Kyte-
Doolittle hydrophilicity (38), surface probability (36), and
Chou Fasman secondary structure indices (13) demonstrated
that this stretch of amino acids has a moderately high antige-
nicity, is fairly hydrophilic, contains a fairly high number of
amino acids with very high surface probability, and is charac-
terized by a series of turns associated with helices and sheets,
respectively, all of which are strong indicators of a region that
is potentially highly immunogenic (Fig. 2). Repeats in OMPs
are widely distributed and perform vital functions in many
bacteria. Some serve as adhesins (25, 26, 56). Others perform
functions such as mediation of adhesion, infection, and trans-
mission of the organism, as well as contributing to protective
immunity (25, 30, 37, 39, 41), and still others confer multidrug
resistance (29). The repeats that constitute PlpE R2 share little
or no sequence homology with the proteins mentioned above.
They do, however, exhibit a similar architectural design, being
comprised of amino acids which may not be identical but are
similar in their properties, such as charge, hydrophilicity, and
surface probability. Some, such as R2 in PlpE, enhance resis-
tance when given as immunogens.
The use of an intact recombinant protein or a subregion of
it as a vaccine or component of a vaccine depends not only on
its inherent immunogenic nature but also on its conservation in
homologous and closely related strains involved in a disease
process. The latter is particularly important in bovine respira-
tory disease in which M. haemolytica S1, S2, and S6 are asso-
ciated with the disease, albeit to different degrees (1, 51).
Previously, whole-cell lysates from 11 serotypes of M. haemo-
lytica were probed by Western blotting with anti-PlpE sera to
demonstrate the presence of the PlpE protein in all of them
(45). However, there was no sequence information showing the
extent of the conservation of this protein among the different
serotypes. PCR amplification and sequencing of the plpE gene
from M. haemolytica S1 and S6, the two serotypes that play the
major roles in M. haemolytica-induced bovine respiratory dis-
ease indicated that the nucleotide sequences were identical (5).
This suggests that a single peptide, viz., R2, can be used as a
vaccine efficacious against two serotypes usually implicated in
the bovine respiratory disease complex. We are currently se-
quencing plpE genes from a larger number of the aforemen-
tioned serotypes collected from different geographical areas
over an extended period of time to determine similarities
among various isolates within S1 and other serotypes, espe-
cially in R2.
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